These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18354388)

  • 1. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
    Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K
    Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers.
    Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Schmidl-Mohl B; Wenzel T; Demal U; Zettinig G; Hornik K; Thau K
    Neuropsychopharmacology; 2007 Aug; 32(8):1661-8. PubMed ID: 17192774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
    Stengler-Wenzke K; Müller U; Barthel H; Angermeyer MC; Sabri O; Hesse S
    Neuropsychobiology; 2006; 53(1):40-5. PubMed ID: 16397403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.
    Hesse S; Müller U; Lincke T; Barthel H; Villmann T; Angermeyer MC; Sabri O; Stengler-Wenzke K
    Psychiatry Res; 2005 Oct; 140(1):63-72. PubMed ID: 16213689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
    Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporter binding in Tourette Syndrome.
    Müller-Vahl KR; Meyer GJ; Knapp WH; Emrich HM; Gielow P; Brücke T; Berding G
    Neurosci Lett; 2005 Sep; 385(2):120-5. PubMed ID: 15936877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).
    Stengler-Wenzke K; Müller U; Angermeyer MC; Sabri O; Hesse S
    Eur Arch Psychiatry Clin Neurosci; 2004 Aug; 254(4):252-5. PubMed ID: 15309396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder.
    Hesse S; Stengler K; Regenthal R; Patt M; Becker GA; Franke A; Knüpfer H; Meyer PM; Luthardt J; Jahn I; Lobsien D; Heinke W; Brust P; Hegerl U; Sabri O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):606-17. PubMed ID: 21232166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram.
    de Win MM; Habraken JB; Reneman L; van den Brink W; den Heeten GJ; Booij J
    Neuropsychopharmacology; 2005 May; 30(5):996-1005. PubMed ID: 15770240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.
    Kim CH; Cheon KA; Koo MS; Ryu YH; Lee JD; Chang JW; Lee HS
    Neuropsychobiology; 2007; 55(3-4):156-62. PubMed ID: 17657168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).
    Pogarell O; Poepperl G; Mulert C; Hamann C; Sadowsky N; Riedel M; Moeller HJ; Hegerl U; Tatsch K
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):521-4. PubMed ID: 16139170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study.
    Shang Y; Gibbs MA; Marek GJ; Stiger T; Burstein AH; Marek K; Seibyl JP; Rogers JF
    J Clin Psychopharmacol; 2007 Feb; 27(1):71-5. PubMed ID: 17224717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder.
    Pogarell O; Hamann C; Pöpperl G; Juckel G; Choukèr M; Zaudig M; Riedel M; Möller HJ; Hegerl U; Tatsch K
    Biol Psychiatry; 2003 Dec; 54(12):1406-13. PubMed ID: 14675805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study.
    Matsumoto R; Ichise M; Ito H; Ando T; Takahashi H; Ikoma Y; Kosaka J; Arakawa R; Fujimura Y; Ota M; Takano A; Fukui K; Nakayama K; Suhara T
    Neuroimage; 2010 Jan; 49(1):121-6. PubMed ID: 19660554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Kugaya A; Sanacora G; Staley JK; Malison RT; Bozkurt A; Khan S; Anand A; Van Dyck CH; Baldwin RM; Seibyl JP; Charney D; Innis RB
    Biol Psychiatry; 2004 Oct; 56(7):497-502. PubMed ID: 15450785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
    Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
    Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo.
    Pirker W; Asenbaum S; Kasper S; Walter H; Angelberger P; Koch G; Pozzera A; Deecke L; Podreka I; Brücke T
    J Neural Transm Gen Sect; 1995; 100(3):247-56. PubMed ID: 8748670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.